Where Margins Hold, Germany Repositions, and Esperion’s $1B Exit

Good morning, ! This week we’re diving into the primary margin protection strategy for the next 12 months, Germany’s biotech evolution, and Experion’s $1B bet on commercial cardio assets. 

Want to advertise in Healthcare 150? Check out our ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

MICROSURVEY

Margins Are Moving From Defense to Design in Healthcare

Healthcare executives are no longer treating margin protection like a temporary cost cutting exercise. The survey results suggest a broader strategic reset is underway.

The top response was portfolio optimization at 24.7%, signaling that healthcare operators are becoming more selective about where capital, talent, and commercial focus actually belong. In other words, trimming low margin exposure is starting to matter more than chasing raw growth.

Close behind, 22.4% pointed to pricing adjustments and renegotiations. That is notable in a sector where reimbursement pressure, labor inflation, and payer scrutiny continue squeezing profitability from multiple angles at once.

Meanwhile, 20.0% of respondents are leaning into automation, AI, and digital transformation. The implication is clear: healthcare leaders increasingly view technology as a margin preservation tool, not just a growth initiative.

Perhaps the most revealing data point: 16.5% still report having no clear strategy. In a sector facing persistent cost pressure, indecision may become the most expensive strategy of all. (More)

HEADLINE OF THE WEEK

Healthcare Bankruptcies Are Climbing Again

Healthcare bankruptcies are making an unwelcome comeback.

The sector logged 12 Chapter 11 filings in Q1 2026, up 33% quarter-over-quarter, according to Gibbins Advisors. That pace would put the industry on track for roughly 48 bankruptcies this year, slightly above 2025 levels and right back near the sector’s seven-year average.

The interesting part isn’t the headline number — it’s where the stress is showing up.

Senior care operators and physician practices accounted for two-thirds of filings, while most cases came from mid-market companies carrying $10m–$50m in liabilities. In other words: this isn’t mega-cap healthcare imploding. It’s the operational middle getting squeezed from every direction at once.

The backdrop remains ugly. Labor costs are still elevated, reimbursement pressure hasn’t eased, and looming Medicaid cuts could remove coverage for thousands of patients. Meanwhile, the expiration of enhanced ACA subsidies is already hitting provider earnings.

Healthcare has always been viewed as “defensive.” Turns out even defensive sectors eventually run into math. (More)

PRESENTED BY EXACT INSIGHT

95%+ qualified. 80%+ recontact. Built for live PE research.

When diligence moves fast, the quality of the respondent matters as much as the speed of the match.

Exact Insight helps PE teams generate more reliable primary research with 95%+ qualification rates, 80%+ recontact success, and access to vetted B2B professionals, healthcare experts, and global consumer panels. Quant, qual, and hybrid studies are built around the specific question at hand and delivered fast enough for live deal and portfolio workflows.

So whether you are pressure-testing a thesis, sizing a market, or validating a niche operator segment, you get cleaner inputs and a research process you can build on.

Scope a Diligence Project →

DEAL OF THE WEEK

Esperion Goes Private in $1.1B ArchiMed Bet on Commercial Cardio Assets

ArchiMed’s take-private of Esperion Therapeutics, valued at up to $1.1B, signals a clear shift in biotech M&A toward de-risked, revenue-linked assets. The firm is paying $3.16 per share, a 58% premium, with an additional $100M tied to commercial milestones across Nexletol, Nexlizet, and newly acquired Enbumyst.

The structure matters. Roughly $40M is contingent on cholesterol drug sales exceeding $350M by 2027, while $60M hinges on Enbumyst surpassing $160M in annual revenue through 2030. This is not pipeline optionality. It is a direct bet on near-term commercial execution.

Timing is not coincidental. Esperion’s $75M Corstasis acquisition added Enbumyst, a drug the company pegs as a $4.6B U.S. opportunity, materially strengthening its revenue narrative just weeks before the buyout.

Why it matters: In a biotech market approaching $2.19T , capital is concentrating around assets with line of sight to revenue, not scientific promise alone. Private equity is stepping in where public markets have discounted commercial-stage biopharma, creating a new valuation floor anchored in sales traction, not pipeline hype. (More)

REGIONAL FOCUS

Germany’s Biotech Market Just Went From Quiet to Competitive

Germany’s biotech M&A market spent the last four years looking more like a venture hangover than a strategic battleground. Median deal size fell from $125M in 2020 to just $23.5M in 2023 as rising rates and risk aversion froze large cap life sciences transactions. Then came 2025.

Median German biotech deal size has now surged to $871.2M, a dramatic jump from $142.5M in 2024. The message is not simply that dealmaking returned. Buyers are writing bigger checks again for scaled platforms with differentiated science, manufacturing capabilities, and European market access.

Why Germany specifically? The country sits at the center of Europe’s biotech supply chain with deep research talent, strong industrial infrastructure, and increasing strategic importance as pharma companies diversify beyond the US and China.

For PE and healthcare investors, this changes the underwriting conversation. Germany is no longer just a sourcing market for smaller venture backed assets. It is becoming a credible arena for large scale biotech consolidation and cross border healthcare M&A.

INTERESTING ARTICLES

GLP-1s driving healthcare cost hikes, employers say

Oscar Health's profit hits $679M, membership rises in Q1

Preparing for the 2026 HIPAA changes: A practical guide for healthcare leaders

"The best way to predict the future is to invent it."

Alan Kay